Trima Non-DEHP Leukoreduced Red Blood Cell In Vivo Recovery Study
Completed · Not applicable · NCT06602804
Conditions: Device Validation of In-vivo Performance
At a glance
- Research payments reported, 2025
- $45,712
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 37
About the trial
- Sponsor
- Terumo BCT
- Tested
- Trima Accel Auto RBC Collection (device)
- Dates
- Started 2024-08-26; completion 2025-01-31
- Results posted
- Yes
This is an in vivo 24-hour in-vivo recovery study of leukoreduced red blood cells (RBCs) collected on the Trima Accel System using Non-DEHP disposable sets and stored for 42 days.
From ClinicalTrials.gov, last updated 2026-02-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Terumo Bct, Inc. reported $45,712 in research payments for this study in 2025 (2 payments).
Products named: Trima Accel
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $45,712
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.